Expert: NICE faced 'difficult decision' over cancer drug

The National Institute for Health and Care Excellence (NICE) faced "difficult decisions" when it deemed a breast cancer drug which can extend sufferers lives by "up to six months" was too expensive, according to a health expert.

Dr Hilary Jones told Daybreak the £90,000 price tag per patient would have meant taking funds away from other vital services the NHS provides.

Advertisement

'Unaffordable' breast cancer drug set to be blocked

A new breast cancer drug which extends women's lives by almost six months could be blocked from routine NHS access because it is too expensive, a health watchdog says.